GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

"NICE approves GSK’s belantamab mafodotin for blood cancer" was originally created and published by Pharmaceutical Technology ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

The US Food and Drug Administration (FDA) announced a forthcoming public advisory committee meeting (AdCom) of the Oncologic Drugs Advisory Committee to review GSK’s marketing application for Blenrep ...

It has been dubbed a “Trojan horse” treatment because it works by being taken into a cancer cell, before releasing a high ...

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for ...

Blenrep is no longer being evaluated for full FDA approval in the United States, as of 2022. At this time, Blenrep has accelerated approval from the FDA to treat multiple myeloma. Accelerated ...

Blenrep plus Velcade and dexamethasone significantly improves overall survival in relapsed/refractory multiple myeloma compared to Darzalex-based regimens. The DREAMM-7 trial met its secondary ...

Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification. Markets Bonds Funds Pre-Market Market Movers Dow Jones Live Your Portfolio ...

If a new package of pivotal data satisfies the FDA, GSK could have another run at the U.S. multiple myeloma market with its previously withdrawn BMCA-targeted antibody-drug conjugate, Blenrep.

Consequently, Blenrep monotherapy as a treatment for relapsed or refractory multiple myeloma was also withdrawn from the EU market. Now that the Blenrep combo has already been approved in Japan ...